Nature Communications (Dec 2021)
Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction
- Caroline Diorio,
- Rawan Shraim,
- Laura A. Vella,
- Josephine R. Giles,
- Amy E. Baxter,
- Derek A. Oldridge,
- Scott W. Canna,
- Sarah E. Henrickson,
- Kevin O. McNerney,
- Frances Balamuth,
- Chakkapong Burudpakdee,
- Jessica Lee,
- Tomas Leng,
- Alvin Farrel,
- Michele P. Lambert,
- Kathleen E. Sullivan,
- E. John Wherry,
- David T. Teachey,
- Hamid Bassiri,
- Edward M. Behrens
Affiliations
- Caroline Diorio
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Rawan Shraim
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Laura A. Vella
- Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Josephine R. Giles
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine
- Amy E. Baxter
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine
- Derek A. Oldridge
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine
- Scott W. Canna
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Sarah E. Henrickson
- Division of Allergy and Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Kevin O. McNerney
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Frances Balamuth
- Division of Emergency Medicine, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Chakkapong Burudpakdee
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Jessica Lee
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Tomas Leng
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Alvin Farrel
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Michele P. Lambert
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Kathleen E. Sullivan
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- E. John Wherry
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine
- David T. Teachey
- Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Hamid Bassiri
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- Edward M. Behrens
- Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-27544-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Multi-inflammatory syndrome in children (MIS-C) can be associated with SARS-CoV-2 infection but can also be similar to other inflammatory syndromes. Here the authors characterise the plasma proteome phenotype in MIS-C and compare to other SARS-CoV-2 related syndromes and find disproportionately high IFN-γ responses in MIS-C patients.
